MBRX Stock Overview
A clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Moleculin Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.77 |
| 52 Week High | US$14.70 |
| 52 Week Low | US$1.50 |
| Beta | 1.88 |
| 1 Month Change | -31.40% |
| 3 Month Change | -25.00% |
| 1 Year Change | -87.03% |
| 3 Year Change | -93.33% |
| 5 Year Change | -97.93% |
| Change since IPO | -99.75% |
Recent News & Updates
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Shareholder Returns
| MBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -2.6% |
| 1Y | -87.0% | -6.3% | 24.5% |
Return vs Industry: MBRX underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: MBRX underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| MBRX volatility | |
|---|---|
| MBRX Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MBRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MBRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 18 | Wally Klemp | moleculin.com |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
Moleculin Biotech, Inc. Fundamentals Summary
| MBRX fundamental statistics | |
|---|---|
| Market cap | US$5.10m |
| Earnings (TTM) | -US$30.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs MBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.15m |
| Earnings | -US$30.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:04 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Moleculin Biotech, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |
| null null | Roth MKM |